in situ carcinoma

in situ carcinoma

See Carcinoma in situ.
References in periodicals archive ?
In situ carcinoma component of 30% with comedo and cribriform patterns was noted in the adjacent areas [Figure 1b].
Long-term follow-up of in situ carcinoma of the breast.
A great deal of the misunderstanding about in situ carcinoma entails the differences in treatment for DCIS and LCIS.
In lesions that showed patterns characteristic of in situ carcinoma, the diameters of the ducts that exhibited this characteristic were measured with a microscope (Nikon model eciipse E-400).
Mammography Appeareances of in situ carcinoma. En Silverstein MJ, Recht A, Lagios MD, editores.
Clinical observations on sixtynine cases of in situ carcinoma of the urinary bladder.
Endocrine ductal carcinoma in situ (E-DCIS) is a distinct subtype of in situ carcinoma, characterized most frequently by a solid expansion of ducts with prominent fibrovascular septae and frequently, spindled cells with nuclear palisading (Figure 2, D).
(5) Collagen IV and laminin have been used for distinguishing invasive carcinoma from in situ carcinoma. (6) Benign or in situ lesions should demonstrate positive staining for MEP markers, whereas invasive carcinomas should show a loss of MEP staining at the periphery of each glandular structure (Figure 2, A through F).
Nonetheless, given that in the absence of conventional invasive carcinoma, these tumors have an indolent clinical course similar to that of DCIS, (42,48) the general consensus is that these lesions should be regarded as in situ carcinoma for staging purposes.
Although most cases of invasive breast cancer do not require ancillary studies for reaching a diagnosis, distinguishing benign proliferative ductal lesions and in situ carcinoma from invasive breast lesions can sometimes be challenging.
(59) For diagnostic questions of invasive versus in situ carcinoma (Figure 5), however, it should be noted that many of the markers show reduced staining in the MECs bordering the in situ lesions, and that this reduction differs between the markers.
In summary, we report a novel case of syringocystadenocarcinoma papilliferum demonstrating the coexistence of invasive and in situ carcinoma, serving as histologic evidence of malignant progression.